PDCD1 and hepatocellular carcinoma: The lower percentage of baseline granulocytes expressing programmed death-1 (PD-1) in patients with HCC receiving atezolizumab-Bevacizumab indicates that these drugs may have better therapeutic effects (Giovannini et al. 2023).